Verrica Pharmaceuticals Inc. (NasdaqCM: VRCA)
Health Care · Pharmaceuticals · US
$4.91
+1.87% today · -19.5% 1Y
Verrica Pharmaceuticals Inc. (NasdaqCM: VRCA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $82.80M and employs 76 people.
Over the last twelve months the share price has lost 19.5%, trading between 3.28 and 9.82.
Tweenvest scores Verrica Pharmaceuticals Inc. across four factors: quality 25/100, value 64/100. Its strongest factor is value.
VRCA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $82.80M
- Revenue (TTM)
- $30.32M
- P/E
- —
- EPS
- -1.88
- Dividend yield
- —
- Beta (5Y)
- 1.49
- 52-week high
- $9.82
- 52-week low
- $3.28
- Avg volume (3M)
- —
- Shares outstanding
- 17.18M
- Employees
- 76
- Next earnings
- —
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
- ISIN
- US92511W2070
- Founded
- 2013
- Listed since
- Jun 15, 2018
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.